BRIEF-FDA Approves Eli Lilly's Foundayo For Adults With Obesity, Weight-Related Medical Conditions

Eli Lilly and Company -0.91%

Eli Lilly and Company

LLY

927.06

-0.91%

April 1 (Reuters) - Eli Lilly and Co LLY.N:

  • ELI LILLY: FDA APPROVED FOUNDAYO FOR ADULTS WITH OBESITY/OVERWEIGHT WITH WEIGHT-RELATED MEDICAL PROBLEMS

  • ELI LILLY: FOUNDAYO CAN BE TAKEN ANY TIME OF DAY WITHOUT FOOD OR WATER RESTRICTIONS

  • ELI LILLY: FOUNDAYO WILL BE AVAILABLE VIA LILLYDIRECT STARTING AT $25/MONTH WITH COMMERCIAL COVERAGE & $149 FOR SELF-PAY

  • ELI LILLY: FOUNDAYO WILL BE AVAILABLE WITH PRESCRIPTIONS ACCEPTED IMMEDIATELY & SHIPPING FROM APRIL 6

  • ELI LILLY: ELIGIBLE MEDICARE PART D INDIVIDUALS MAY GET FOUNDAYO FOR $50/MONTH, FROM AS SOON AS JULY 1, 2026

  • ELI LILLY: USE OF FOUNDAYO WITH OTHER GLP-1 RECEPTOR AGONIST MEDICINES IS NOT RECOMMENDED

  • ELI LILLY: FOUNDAYO MAY CAUSE TUMORS IN THYROID, INCLUDING THYROID CANCER

  • ELI LILLY: NOT KNOWN WHETHER FOUNDAYO IS SAFE & EFFECTIVE FOR USE IN CHILDREN

Further company coverage: LLY.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.